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Winning battles sometimes leave innocent bystanders
wounded or even killed on the ground. Although a surgical
intervention may be successful in treating a diseased organ, it
may affect the heart, resulting in ischemia, infarction, or life-
threatening dysrhythmias. The disease is conquered, but the
patient may die of a de novo or decompensated heart disease.
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Weiser et al. (1) recently estimated that 234 million major
surgical procedures are performed every year worldwide. An
exaggerated neuroendocrine and sympathetic response as
part of the stress response to anesthesiology and surgical
maneuvers, as well as the inﬂammatory and hypercoagulable
state induced by surgery and transient hypoxia elicited by
anesthesia/analgesia, hypothermia, and bleeding or anemia,
can unmask latent coronary artery disease, triggering
thrombotic and ischemic events in the patient at risk (2).
The same pathophysiological triggers may account for
other life-threatening cardiovascular events, such as acute
decompensated heart failure and major arrhythmias.
Cardiovascular events are severe and frequent complica-
tions during noncardiac surgery (2–4), with a major cardiac
event occurring in either 3.9% of patients with or at risk
of cardiac disease or in 1.4% of unselected patients (2).
A recent large (n ¼ 15,133) prospective study evaluating
post-operative high-sensitivity cardiac troponin T levels and
30-day mortality after noncardiac surgery revealed that an
elevation greater than the 99th percentile was present in 12%
of subjects (5). A high-risk type of procedure matters: the
incidence of perioperative myocardial ischemia and infarc-
tion in vascular surgery ranged from 14% to 47% and from
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troponin I or T (6).
Although the perioperative event rate has decreased over
the past 30 years as a consequence of improvement in
anesthesiology and surgical techniques, perioperative cardiac
complications remain a signiﬁcant problem, whereas the
most widely accepted current risk prediction model, the
Revised Cardiac Risk Index (7) (based on the type of
surgery; history of cardiac, cerebrovascular, or kidney disease;
and pre-operative treatment with insulin), has recognized
limitations (8,9).
The use of cardiac biomarkers in clinical settings that put
patients at risk for cardiac events has been successful in
improving risk stratiﬁcation, guiding medical decision
making, and preventing cardiac disease progression. This is
the case in patients with neoplastic disease receiving
potentially cardiotoxic drug treatment, in whom the com-
bination of screening by troponin assay and biomarker-
oriented use of angiotensin-converting enzyme inhibitors
has been proven effective (10). The prognostic value of
cardiac biomarkers in patients undergoing noncardiac sur-
gery is supported by growing evidence. The post-operative
troponin T level is associated with an outcome with graded
response, with up to a 16.9% 30-day mortality in those with
a troponin T level >0.30 ng/ml (2). Increasing troponin I,
assayed by a regularly scheduled post-operative protocol,
showed a 3-fold increase in the probability of detecting
myocardial injury, compared with clinically based measure-
ments, and a dose-response association with increased
mortality in moderate- to high-risk patients in a retrospec-
tive cohort analysis of 51,701 consecutive patients (11).
Conversely, elevated pre- and post-operative B-type natri-
uretic peptide (NP) concentrations have been shown to be
powerful independent predictors of perioperative cardiovas-
cular complications (i.e., mortality, myocardial infarction,
and heart failure) (12,13).
However, most recent guidelines are controversial in
regard to the use of biomarkers in the setting of noncardiac
surgery. The 2007 National Academy of Laboratory
Medicine Guideline has suggested the perioperative assay
of troponins to detect silent ongoing heart damage or for
post-operative risk stratiﬁcation in high-risk subsets, such as
those undergoing vascular surgery, and denied evidence to
recommend the routine measurement of brain natriuretic
peptide (BNP) and N-terminal fragment of proBNP (NT-
proBNP) before or after cardiac surgery (14). This indication
is debated by the 2009 American College of Cardiology
Foundation/American Heart Association guidelines (15),
which restricted troponin use to patients with electrocar-
diographic changes and chest pain. European 2009 guide-
lines did not recommend routine biomarker sampling to
prevent cardiac events among patients undergoing noncar-
diac surgery (3), whereas pre-operative measurement of
BNP or NT-proBNP was recommended to obtain prog-
nostic information on perioperative and late cardiac events in
high-risk patients (3).
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182In this issue of the Journal, Rodseth et al. (16) have
evaluated whether the measurement of post-operative BNP
and NT-proBNP levels enhance risk stratiﬁcation in adult
patients undergoing noncardiac surgery, compared with
a single pre-operative BNP and NT-proBNP assay or the
delta of concentration. Rodseth et al. (16) conducted a meta-
analysis, including individual data of 2,179 patients from
18 eligible studies, to determine whether the addition of
post-operative BNP or NT-proBNP values enhanced the
prediction of the composite of death and nonfatal myocar-
dial infarction at 30 and 180 days after surgery. They
found that post-operative BNP and NT-proBNP were the
strongest independent predictors of the primary outcome
and provided an additive value to a risk prediction model
containing pre-operative assays, improving model ﬁt and
risk classiﬁcation.
Cardiac NPs, which include BNP and its related peptide
NT-proBNP, constitute a complex family of peptide hor-
mones produced and secreted by the human heart (17).
Under physiological conditions, ventricular myocardium pro-
duces only a limited amount of BNP; conversely, several
pathophysiological mechanisms, some associated with chronic
disease (e.g., ventricular hypertrophy/ﬁbrosis and left ven-
tricular systolic/diastolic dysfunction) and transient condi-
tions, such as those occurring during surgery stress (e.g.,
inﬂammation and myocardial ischemia/hypoxia), stimulate
BNP production and release from ventricular cardiomyocytes
(17). International guidelines recommend the measurement
of BNP for the diagnosis, risk stratiﬁcation, and follow-up
of patients with chronic or acute heart failure (18), as well as
for risk assessment in patients with symptoms consistent with
acute coronary syndrome (19).
Rodseth et al. (16) are to be congratulated for their
successful effort. Their ﬁndings may affect future patient
management. The predictive value of the level of post-
operative B-type NPs might reﬂect the inﬂuence of proce-
dural maneuvers and cardiac/systemic complications after
surgery and may be used to identify a subset of patients at
major risk, requiring enhanced diagnostic and therapeutic
effort. However, there are still relevant issues to be solved.
Is the prognostic value of an early increase of troponins or
NP concentration after noncardiac surgery (<3 days) inde-
pendent and additive? Although a single report seems to
be negative in this respect (20), Rodseth et al. (16) have
a database with individual data containing both troponin
and NP and may be able to give a preliminary answer to this
crucial question. Yet, an early concomitant elevation of
either biomarker could recognize the same ischemic trigger
and provide only redundant information. Conversely, at least
a subset of patients with post-operative negative troponin
might show an NP increase due to nonischemic determi-
nants. Because the clinical value of a marker/multimarker
strategy should be assessed by its effect on patient mana-
gement and outcomes, in this instance, diagnostic decision
making should consider possible ongoing, life-threatening
noncoronary pathologies (e.g., acute decompensated chronicheart failure and pulmonary embolism), with adoption of
speciﬁc therapeutic options, likely different from those rec-
ommended for preventing ischemic events (i.e., continuation
of chronic titrated cardioselective beta-blocker, statin, and
aspirin treatment).
Surgeons, anesthesiologists, and clinicians should hear
their patient’s heart whispering its silent pain and damage
while secreting its hormones and releasing proteins into the
bloodstream. However, to improve perioperative risk strati-
ﬁcation in noncardiac surgery, and going beyond established
clinical scores with the use of cardiac biomarkers, prospective
studies are needed, speciﬁcally aimed at evaluating the
independence of troponin and NP predictive value even in
mid- and long-term periods, and at assessing the usefulness
of NP levels as a guide to therapy affecting prognosis.
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